List view / Grid view
25 September 2014 | By kdm communications
Microfluidics specialist Dolomite has teamed up with Lab on a Chip and the Chemical and Biological Microsystems Society to create the first ever MicroTAS Video Competition...
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
25 September 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015 and will become Deputy Chairman with effect from 1 April 2015...
25 September 2014 | By AstraZeneca
AstraZeneca announced that MedImmune, its global biologics research and development arm, and Cancer Research UK, with its commercial arm, Cancer Research Technology (CRT), have entered into an innovative collaboration to establish a joint laboratory in Cambridge, UK...
25 September 2014 | By Helsinn
Helsinn Group announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress...
25 September 2014 | By Photocure ASA
Cysview® improves detection of Non-Muscle Invasive Bladder Cancer (NMIBC) beyond that achieved with current standard of care...
24 September 2014 | By Sigma-Aldrich
Sigma-Aldrich Corporation’s SAFC® Commercial custom manufacturing services business unit, and Baxter’s BioPharma Solutions business have established a collaborative manufacturing agreement...
24 September 2014 | By Gilead
Gilead Sciences, Inc. announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives...
24 September 2014 | By Abbott
Abbott announced the expiration of the tender offer for the purchase from U.S. holders of the ordinary shares of CFR Pharmaceuticals S.A., a Chilean corporation...
24 September 2014 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics Company, will present a symposium and three poster publications at the forthcoming 19th North American ISSX Meeting / 29th JSSX Meeting (ISSX/JSSX 2014) from October 19th to 23rd in San Francisco, USA...
24 September 2014 | By Sigma-Aldrich
Merck KGaA , a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich announced that they have entered into a definitive agreement under which Merck KGaA, Darmstadt, Germany, will acquire Sigma-Aldrich for $17.0 billion...
24 September 2014 | By SMi Group
Set to take place on 21st and 22nd January 2015, the 4th annual event in the sell-out Pharmaceutical Microbiology series will bring together all levels of industry professionals, providing essential insights into the latest advancements in practice and technology, developments in regulation and the global harmonisation of evolving microbiology methods...
24 September 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced plans to build a 650,000-square-foot office building on company-owned land at the intersection of Princeton Pike and Interstate 295 in Lawrenceville, New Jersey...
23 September 2014 | By nLife Therapeutics
The funding will help characterize the mechanism of action of nLife’s lead compound NLF-PD-1233 in a Parkinson disease model and find a proper dose to engage clinical development...
23 September 2014 | By ImmuSmol
ImmuSmol is announcing it has raised 500 000 euros to progress its cancer immunotherapy program to in vivo proof-of-concept...
